Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 5;27(4):e353-e356.
doi: 10.1093/oncolo/oyac026.

Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors

Cristina Mullenix  1 , Madison Ballman  1 , Haobin Chen  2 , Shannon Swift  1 , Meredith J McAdams  1 , Yo-Ting Tsai  3 , Renee N Donahue  3 , Trina Poretta  4 , Sarthak Gupta  5 , Patrick J Loehrer  6 , Jeffrey Schlom  3 , James L Gulley  3   7 , Arun Rajan  1
Affiliations

Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors

Cristina Mullenix et al. Oncologist. .

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers. However, activation of the immune system can occasionally cause life-threatening toxicity involving critical organs. Induction of immune-mediated toxicity is a significant concern for patients with thymic epithelial tumors (TETs) due to defects in immune tolerance. An increased risk of skeletal and cardiac muscle inflammation following treatment with ICIs is well recognized in patients with advanced TETs. However, uncommon musculoskeletal and rheumatic complications can also occur. The cases presented in this report highlight the spectrum of presentation of immune-mediated, joint-predominant musculoskeletal adverse events in patients with advanced TETs treated with ICIs, including polymyalgia rheumatica-like illness and inflammatory arthritis.

Keywords: immunotherapy; inflammatory arthritis; myositis; polymyalgia rheumatica; thymic epithelial tumors.

PubMed Disclaimer

References

    1. Bagchi S, Yuan R, Engleman EG.. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance Annu Rev Pathol. 2021;16:223-249. doi:10.1146/annurev-pathol-042020-042741 - DOI - PubMed
    1. Melissaropoulos K, Klavdianou K, Filippopoulou A, et al. . Rheumatic manifestations in patients treated with immune checkpoint inhibitors Int J Mol Sci . 2020;21:3389. - PMC - PubMed
    1. Rajan A, Mullenix C, Shelat M, et al. . The role of immunotherapy for management of advanced thymic epithelial tumors: a narrative review Mediastinum 2021;5:23. doi:10.21037/med-20-62 - DOI - PMC - PubMed
    1. Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. . 2012 Provisional classification criteria for Polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology Collaborative Initiative Ann Rheum Dis. 2012;71:484-492. doi:10.1136/annrheumdis-2011-200329 - DOI - PMC - PubMed
    1. Calabrese C, Cappelli LC, Kostine M, et al. . Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature. RMD Open 2019;5:e000906. doi:10.1136/rmdopen-2019-000906 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances